文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

低剂量静脉联合吸入多黏菌素B对比单用静脉多黏菌素B治疗重症广泛耐药革兰阴性菌呼吸机相关性肺炎:多中心配对病例对照研究

Low-dose intravenous plus inhaled versus intravenous polymyxin B for the treatment of extensive drug-resistant Gram-negative ventilator-associated pneumonia in the critical illnesses: a multi-center matched case-control study.
PubMed 文献 · Ann Intensive Care · 2022-08-08
一句话结论在广泛耐药革兰阴性菌VAP中,低剂量吸入联合静脉多黏菌素B未提高临床治愈率(43.2% vs 27.3%,p=0.066),但与良好临床结局独立相关(aOR 2.63)。

该回顾性多中心观察性队列研究于2018年1月1日至2020年1月1日在中国8个ICU开展,比较吸入联合静脉多黏菌素B与单用静脉多黏菌素B治疗广泛耐药革兰阴性菌VAP的疗效与安全性。经年龄(±5岁)、性别、脓毒性休克及多黏菌素B启动时APACHE II评分(±4分)匹配后纳入132例(联合组44例、静脉组88例)。临床治愈率(43.2% vs 27.3%,p=0.066)、细菌清除率(36.4% vs 23.9%,p=0.132)、VAP相关死亡率(27.3% vs 34.1%,p=0.428)及全因死亡率(34.1% vs 42.0%,p=0.378)均无显著差异,但联合治疗与良好临床结局改善相关(77.3% vs 58.0%,p=0.029)。作者结论认为加用低剂量吸入多黏菌素B未提供有效的临床治愈和细菌清除。

要点

  • 匹配后联合组44例与静脉组88例比较,临床治愈率43.2% vs 27.3%(p=0.066),无显著差异。
  • 良好临床结局(临床治愈或临床改善)联合组77.3% vs 静脉组58.0%(p=0.029)。
  • 细菌清除率36.4% vs 23.9%(p=0.132),VAP相关死亡率27.3% vs 34.1%(p=0.428),全因死亡率34.1% vs 42.0%(p=0.378),均无显著差异。
  • 加用吸入多黏菌素B是良好临床结局的独立相关因素(aOR 2.63,95%CI 1.06–6.66,p=0.037)。
  • 无患者因不良事件需要停用多黏菌素B。

适用人群与场景

  • 2018年1月1日至2020年1月1日在中国8个ICU住院、接受多黏菌素B治疗且微生物学确诊为广泛耐药革兰阴性菌VAP的患者。
  • 匹配变量为年龄(±5岁)、性别、脓毒性休克及多黏菌素B启动时APACHE II评分(±4分),匹配后纳入132例(联合组44例、静脉组88例)。

处置流程与药物剂量

  • 干预为低剂量静脉多黏菌素B联合吸入多黏菌素B,对照为单用低剂量静脉多黏菌素B;原文未给出具体剂量、给药频次与疗程。

研究设计与关键结果

  • 回顾性多中心观察性队列研究,8个ICU,2018年1月1日至2020年1月1日,初始151例接受静脉多黏菌素B、46例接受吸入联合静脉多黏菌素B,匹配后132例(联合组44例、静脉组88例)。
  • 主要分离病原为广泛耐药肺炎克雷伯菌(n=83,42.1%)。
  • 主要终点临床治愈率:联合组43.2% vs 静脉组27.3%(p=0.066),无显著差异。
  • 良好临床结局:联合组77.3% vs 静脉组58.0%(p=0.029)。
  • 细菌清除率:联合组36.4% vs 静脉组23.9%(p=0.132);VAP相关死亡率:联合组27.3% vs 静脉组34.1%(p=0.428);全因死亡率:联合组34.1% vs 静脉组42.0%(p=0.378),均无显著差异。
  • 亚组(内科病因入院、感染广泛耐药肺炎克雷伯菌、无菌血症、免疫抑制状态)的OR均倾向于联合治疗。
  • 加用吸入多黏菌素B是良好临床结局的独立相关因素(aOR 2.63,95%CI 1.06–6.66,p=0.037)。
  • 无患者因不良事件需要停用多黏菌素B。

证据类型、等级与局限

  • 证据类型:回顾性多中心观察性队列研究(配对病例对照分析)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,在广泛耐药革兰阴性菌所致VAP中,加用低剂量吸入多黏菌素B未提供有效的临床治愈和细菌清除。
  • 加用吸入多黏菌素B与良好临床结局独立相关(aOR 2.63,95%CI 1.06–6.66,p=0.037),但主要终点临床治愈率无显著差异。
  • 无患者因不良事件需要停用多黏菌素B。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The mortality of extensively drug-resistant Gram-negative (XDR GN) bacilli-induced ventilator-associated pneumonia (VAP) is extremely high. The purpose of this study was to compare the efficacy and safety of inhaled (IH) plus intravenous (IV) polymyxin B versus IV polymyxin B in XDR GN bacilli VAP patients.

METHODS: A retrospective multi-center observational cohort study was performed at eight ICUs between January 1st 2018, and January 1st 2020 in China. Data from all patients treated with polymyxin B for a microbiologically confirmed VAP were analyzed. The primary endpoint was the clinical cure of VAP. The favorable clinical outcome, microbiological outcome, VAP-related mortality and all-cause mortality during hospitalization, and side effects related with polymyxin B were secondary endpoints. Favorable clinical outcome included clinical cure or clinical improvement.

RESULTS: 151 patients and 46 patients were treated with IV polymyxin B and IH plus IV polymyxin B, respectively. XDR Klebsiella pneumoniae was the main isolated pathogen (n = 83, 42.1%). After matching on age (± 5 years), gender, septic shock, and Apache II score (± 4 points) when polymyxin B was started, 132 patients were included. 44 patients received simultaneous IH plus IV polymyxin B and 88 patients received IV polymyxin B. The rates of clinical cure (43.2% vs 27.3%, p = 0.066), bacterial eradication (36.4% vs 23.9%, p = 0.132) as well as VAP-related mortality (27.3% vs 34.1%, p = 0.428), all-cause mortality (34.1% vs 42.0%, p = 0.378) did not show any significant difference between the two groups. However, IH plus IV polymyxin B therapy was associated with improved favorable clinical outcome (77.3% vs 58.0%, p = 0.029). Patients in the different subgroups (admitted with medical etiology, infected with XDR K. pneumoniae, without bacteremia, with immunosuppressive status) were with odd ratios (ORs) in favor of the combined therapy. No patient required polymyxin B discontinuation due to adverse events. Additional use of IH polymyxin B (aOR 2.63, 95% CI 1.06, 6.66, p = 0.037) was an independent factor associated with favorable clinical outcome.

CONCLUSIONS: The addition of low-dose IH polymyxin B to low-dose IV polymyxin B did not provide efficient clinical cure and bacterial eradication in VAP caused by XDR GN bacilli. Keypoints Additional use of IH polymyxin B was the sole independent risk factor of favorable clinical outcome. Patients in the different subgroups were with HRs substantially favoring additional use of IH polymyxin B. No patients required polymyxin B discontinuation due to adverse events.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Liu J, Shao M, Xu Q, et al. Low-dose intravenous plus inhaled versus intravenous polymyxin B for the treatment of extensive drug-resistant Gram-negative ventilator-associated pneumonia in the critical illnesses: a multi-center matched case-control study. Ann Intensive Care. 2022. PMID: 35934730. doi:10.1186/s13613-022-01033-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。